As CEO at Response Biomedical (TSX: RBM, OTCQB: RPBIF), Mr. Purvin directed the development, manufacturing and worldwide marketing of a variety of medical tests and test machines used by medical laboratories and government authorities. Prior to joining Response Biomedical, Mr. Purvin was the Chairman and CEO of Calibra Medical, Inc. At Calibra, he and his team developed and gained FDA clearance for a unique, small, wearable insulin delivery device. Johnson & Johnson acquired Calibra Medical in 2012. Prior to Calibra, Mr. Purvin was Chairman and CEO of Metrika, Inc. There, he and his team developed a handheld, point-of-care, semi-disposable, finger stick-based, HbA1c test which the company sold directly to physicians, consumers and other companies, worldwide. Bayer acquired Metrika in 2006.
Prior to Metrika, Mr. Purvin ran the Interventional Products Division of Datascope Corporation as its President. At Datascope, Mr. Purvin was responsible for marketing a large line of interventional cardiology and radiology devices to hospitals, worldwide.
Prior to Datascope, Mr. Purvin served as Vice President, General Manager, in GlaxoSmithKline’s $4B Consumer Healthcare division where he marketed scores of well-known, highly advertised consumer packaged goods.
Mr. Purvin started his career at Bristol-Myers Squibb, where he marketed both branded and generic pharmaceuticals and consumer products to both physicians and consumers.
Mr. Purvin served on the Board of Directors at Cardica, Inc [NASDQ: CRDC] for 5 years through 2014. Cardica markets a unique coronary bypass anastomosis connection device to cardiothoracic surgeons, worldwide, and is currently developing a unique, multi-staple-firing surgical stapler line. Mr. Purvin was Chair of Cardica’s Compensation Committee and was a member of its Audit and Finance Committees.
Mr. Purvin earned his B.A. from Brown University and his M.B.A from The Wharton School, University of Pennsylvania.